Results 191 to 200 of about 8,764,462 (319)

DeepSpaceDB: a spatial transcriptomics atlas for interactive in-depth analysis of tissues and tissue microenvironments. [PDF]

Nucleic Acids Res
Honcharuk V, Zainab A, Horimoto Y, Takemoto K, Diez D, Kawaoka S, Vandenbon A.   +6 more
europepmc   +1 more source

Deep Neural Networks for High Dimension, Low Sample Size Data

International Joint Conference on Artificial Intelligence, 2017
Bo Liu, Ying Wei, Yu Zhang, Qiang Yang
semanticscholar   +1 more source

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

Early Detection of Porcine Reproductive and Respiratory Syndrome Virus Outbreak: Combination of Methods. [PDF]

Vet Sci
Gao C, Wang Y, Liu M, Yang H, Jiao W, Ding X, Zhao Y, Fan H.   +7 more
europepmc   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Dietary intake, quality, and assessment tools in individuals with problematic alcohol use: a scoping review and meta-analysis. [PDF]

Transl Psychiatry
Barb JJ, King LC, Nanda S, Barnett D, Darcey VL, Yang S, Turner S, Ahmed A, Maki KA, Vizioli C, Butera G, Farokhnia M, Wallen GR, Leggio L.   +13 more
europepmc   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Estimating COVID-19 incidence and prevalence using lateral flow tests in England and Scotland, 2023-2024. [PDF]

Nat Commun
Fyles M, Mellor J, Paton RS, Overton CE, Phillips AM, Glaser A, Ward T.   +6 more
europepmc   +1 more source

Class IIa HDACs forced degradation allows resensitization of oxaliplatin‐resistant FBXW7‐mutated colorectal cancer

Molecular Oncology, EarlyView.
HDAC4 is degraded by the E3 ligase FBXW7. In colorectal cancer, FBXW7 mutations prevent HDAC4 degradation, leading to oxaliplatin resistance. Forced degradation of HDAC4 using a PROTAC compound restores drug sensitivity by resetting the super‐enhancer landscape, reprogramming the epigenetic state of FBXW7‐mutated cells to resemble oxaliplatin ...
Vanessa Tolotto, Nicolò Gualandi, Ylenia Cortolezzis, Raffaella Picco, Monica Colitti, Francesca D'Este, Mariachiara Gani, Wayne W. Hancock, Giovanni Terrosu, Cristina Degrassi, Francesca Agostini, Claudio Brancolini, Luigi E. Xodo, Eros Di Giorgio   +13 more
wiley   +1 more source

A countrywide study on post-COVID-19 condition in Brazil: the Epicovid 2.0. [PDF]

Int J Epidemiol
Wehrmeister FC, Menezes AMB, Dalcolmo M, Prendergast ECC, Batista TGS, Leão OAA, Blumenberg C, Vinholes Siqueira F, Struchiner CJ, Victora CG, Hallal PC.   +10 more
europepmc   +1 more source